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Highlights  
• hsEH is a key regulator of cardiovascular homeostasis  
• A HEK293-F mammalian expression system for hsEH full-length (FL) was developed  
• An E. coli expression system for the hsEH C-terminal Domain (CTD) was established  
• Both proteins exhibited the same enzymatic specific activity in vitro  
• The CTD preparation provides benefits of easy operation, and high yield and purity  
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Abbreviations 
EETs (epoxieicosatrienoic acids), AR9281 (1-(1-acetylpiperidin-4-yl)-3-adamantan-1-
ylurea), AUDA (12-[[(tricyclo[3.3.1.13,7]dec-1-ylamino)carbonyl]amino]-dodecanoic acid), 
GSK2256294 ((1R,3S)-N-(4-cyano-2-(trifluoromethyl)benzyl)-3-((4-methyl-6-
(methylamino)-1,3,5-triazin-2-yl)amino)cyclohexanecarboxamide), PHOME (3-phenyl-
cyano(6-methoxy-2-naphthalenyl) methyl ester-2-oxiraneacetic acid), 6M2N (6-methoxy-2-
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naphtaldeyde), DTT (dithiothreiotol), TCEP (tris(2-carboxyethyl)phosphine), IMAC 
(immobilised metal affinity chromatography), SDS-PAGE (sodium dodecyl sulphate 
polyacrylamide electrophoresis). BTS (benzylthio-Sepharose), SEC (size exclusion 
chromatography).   
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Abstract  
The human soluble Epoxide Hydrolase (hsEH) is an enzyme involved in the hydrolysis of 
endogenous anti-inflammatory and cardio-protective signalling mediators known as 
epoxyeicosatrienoic acids (EETs). EETs’ conversion into the corresponding diols by hsEH 
generates non-bioactive molecules, thereby the enzyme inhibition would be expected to 
enhance the EETs bioavailability, and their beneficial properties. Numerous inhibitors have 
been developed to target the enzyme, some of which are showing promising antihypertensive 
and anti-inflammatory properties in vivo. Thus far, the preparation of the recombinant 
enzyme for enzymatic and structural in vitro studies has been performed mainly using a 
baculovirus expression system. More recently, it was reported that the enzyme could be 
exogenously expressed and isolated from E. coli, although limited amounts of active protein 
were obtained. We herein describe two novel methods to yield pure recombinant enzyme. 
The first describes the expression and purification of the full-length enzyme from eukaryotic 
cells HEK293-F, whilst the second concerns the C-terminal domain of hsEH obtained from 
the cost-effective and rapid E. coli prokaryotic system. The two methods successfully 
generated satisfactory amounts of functional enzyme, with virtually identical enzymatic 
activity. Overall, the protocols described in this paper can be employed for the recombinant 
expression and purification of active hsEH, to be used in future biomedical investigations and 
for high-throughput inhibitors screenings, to effectively identify drug candidates for the 
treatment of cardiovascular diseases.  
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Introduction  
The human soluble Epoxide Hydrolase (hsEH – EC 3.3.2.10) is composed by two 
independently folded domains [1–3], an N-terminal domain (NTD) with phosphatase activity 
[3,4], and a C-terminal domain (CTD) which performs the hydrolysis of epoxy-fatty acids 
[3,5–7]. The CTD activity is involved in the homeostatic regulation of the cardiovascular 
tone, mainly through the hydrolysis of the epoxyeicosatrienoic acids (EETs), endothelial-
derived hyperpolarising factors able to induce the relaxation of the vasculature in organs such 
as heart, kidneys, and many others [8–10]. The products of the EETs hsEH-mediated 
hydration, namely dihydroxyeicosatrienoic acids (DHETs), have a considerably reduced 
biological activity [10]. In the last 30 years, great efforts have been directed towards 
designing and synthesising effective inhibitors of hsEH CTD activity, with the ultimate aim 
to enhance the EETs’ bioavailability. This led to the discovery of several compounds able to 
reduce the enzyme hydrolytic activity in vitro with high potency and with promising in vivo 
efficacy in animal models of hypertension, atherosclerosis, diabetes, inflammation, pain, 
pulmonary disease and immunological disorders [11,12]. Of the thousands of compounds 
developed thus far, only few reached clinical trials. The two sEH inhibitor AR9281 [13] and 
AUDA [14] failed in a phase IIa study due to lack of efficacy [15,16]. Two phase I clinical 
trials with the GlaxoSmithKline compound GSK2256294 [17] have been recently completed. 
The results are still pending, even though no positive outcomes have been revealed yet 
[18,19]. As none of the thus far established antagonists exhibited absorption, distribution, and 
pharmacokinetics properties suitable for advanced clinical trials, the search for novel drug 
candidates is still an active field [12]. The rapid and cost-effective development of new 
compounds depends on the easy and manageable protocols of preparation of the hsEH. The 
great majority of the drug discovery studies on hsEH have been carried out producing the 
enzyme from S. frugiperda insect cells, via baculovirus recombinant expression [20–22]. 
However, this method is time-consuming and laborious. More recently, Nishi et al. [23] 
reported a protocol for the recombinant expression of the full-length human enzyme in E. 
coli. The purified enzyme showed virtually identical specific activity and inhibition 
properties of the recombinant enzyme prepared from insect cells. However, the yield of 
purified hsEH full-length (hsEH FL) obtained from prokaryotic cells was reported to be 
rather low (around 2 mg/L). Herein, we present a novel protocol of expression and 
purification of the recombinant hsEH FL, that yields milligrams of pure and active 
recombinant enzyme. This alternative method utilises the mammalian cells FreeStyle™ 
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HEK293 (HEK293-F) [24]. Beyond the FL protein, Tanaka et al. [25] reported recently the 
first structure of the hsEH CTD, in complex with two novel inhibitors of the epoxy-
hydrolytic activity of the enzyme, indicating that the CTD in isolation could be utilised to 
screen new libraries of hsEH antagonists. Although the CTD was obtained by recombinant 
expression in E. coli, very little detail on the protein expression and purification system was 
provided in the previous report. In this paper, we describe a thorough protocol of prokaryotic 
expression of the isolated CTD, along with an optimised purification method to yield 
milligram amounts per litre of pure protein for biological investigations and drug discovery 
studies.  
In addition to protein cloning, expression, and purification of the hsEH FL and CTD, the 
enzymatic specific activity of the recombinant enzymes was also compared and will be herein 
described. 
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Materials and Methods 
Cloning of hsEH FL in mammalian expression vector 
The cDNA of hsEH FL was kindly provided by Dr C Morisseau (UC Davis) and was cloned 
into the pcDNA3.1D/V5-His-TOPO® vector (Invitrogen) using the pcDNA3.1 Directional 
TOPO® Expression Kit (Invitrogen). The hsEH FL cDNA was PCR-amplified using primers 
designed to facilitate directional cloning (Table 1), as detailed in the kit instructions, 
generating a blunt-end PCR product that was mixed using a molar ratio of 1:1 of 
insert:TOPO® vector. The mixture was then used to chemically transform One shot® TOP10 
E. Coli competent cells. Successful cloning was confirmed by sequencing (MWG Eurofins). 
The mammalian expression vector cloned with the hsEH FL cDNA was finally amplified in 
E. coli DH5α C2987 competent cells (NEB) and purified using the Pure Yield™ Plasmid 
Maxiprep system (Promega), out of a 0.5 L bacterial culture.  
Expression of hsEH FL in HEK293-F cells 
A vial containing 1×107 viable FreeStyle™ 293-F cells (HEK293-F – ThermoFisher 
Scientific) was transferred into a disposable Erlenmeyer flask (Sigma) previously filled with 
30 mL of pre-warmed FreeStyle 293 Expression Serum-Free Medium™ (SFM – 
ThermoFisher Scientific). The cells were cultured for two days at 37°C, 8% CO2, and 100 
rpm, in a shacking incubator, up to a density of 1-3×106 cells/mL and 90% viability. Cells 
were sub-cultured four times, every two days of incubation, in 30 mL of fresh SFM to 0.2-
0.5×106 cells/mL. During the fifth and last passage, the cells were seeded in 125 mL of fresh 
medium to 1×106 cells/mL. After 48 hours, the cells were prepared for transfection, being 
resuspended at a cell density of 2×106 cells/mL in 250 mL of fresh pre-warmed SFM. The 
vector and the transfection agent polyethylenimine (Sigma) were added to the cells to a final 
concentration of respectively 3 µg/mL and 9 µg/mL. After 24 hours, the culture was diluted 
1:1 in pre-warmed SFM supplemented with 2.2 mM Valproic Acid (Sigma). Three days later 
the cells were collected by centrifugation at 1200 rpm for 20 minutes at room temperature 
and stored at -20°C.  
Cloning of hsEH CTD in bacterial expression vector 
A modified pET3a plasmid, containing a hexahistidine tag (His-tag) and a TEV (tobacco etch 
virus) cleavage site (MHHHHHHSTENLYFQGSS) in the multiple cloning site, was 
provided by the Protein Production Facility of King’s College London. The cDNA of the 
hsEH CTD (amino acids 230-555) was cloned in the plasmid using the IN-Fusion® cloning 
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ligation-independent system (Clontech Laboratories Inc.) [26]. The cDNA was PCR-
amplified with the DNA polymerase KOD Hot Start Master Mix (EMD Millipore), using 
“chimeric” primers designed with the IN-fusion® primer design web tool, characterised by a 
sequence that overlaps with the gene of interest, and a region complementary to the vector 
(Table 2). The template used was the mammalian expression vector containing the hsEH FL, 
described above. The plasmid pET3a was double digested for 3 hours at 37°C with 
BamHI/PstI (NEB), and the restriction enzymes were inactivated for 20 minutes at 80°C. 
Plasmid and insert were mixed with a molar ratio of 1:3 respectively, and incubated with the 
In-Fusion HD Enzyme Premix for 30 minutes at 50°C. The DNA was then used to transform 
DH5α C2987 E. coli competent cells. Successful cloning was confirmed by sequencing 
(Source Bioscience). 
Expression of hsEH CTD in E. coli 
The pET3a containing hsEH CTD cDNA was transformed in chemically competent 
Ros2TM(DE3) (EMD Millipore). A single colony of transformed cells was inoculated in 50 
mL of ZYP5052 auto-induction medium [27] and cultured at 30°C and 200 rpm overnight. 
The culture was diluted 1:100 in 3×1 L Erlenmeyer flasks filled up with fresh ZYP5052 
medium and cultured at 37°C and 200 rpm until the optical density of 0.5 was reached. The 
incubation temperature was then lowered to 18°C and cells cultured for 24 hours at 200 rpm. 
At the end of the incubation, the cells where centrifuged at 5000×g for 30 min at 4°C and the 
pellets stored at -20°C. 
Ni2+-IMAC chromatography  
The pellets obtained from mammalian cells growths were resuspended in 5 mL/g of wet cells 
of lysis buffer (50 mM Tris-HCl pH 8, 300 mM NaCl, 10 mM imidazole, 5 % glycerol, 2 mM 
PMSF, 2 mM MgCl2, 0.2 mM EDTA, 15 µg/mL benzamidine, a tablet of cOmplete™ 
protease inhibitor cocktail (Roche) per 50 mL of buffer), and the cells broken with three 
thaw-and-freeze cycles in liquid nitrogen. Pellets from bacterial cultures were resuspended in 
2 mL/g of wet cells of lysis buffer (same as before, added with 0.01 g of lysozyme), to be 
sonicated on ice with a Vibra-Cell™ sonicator (Sonics) for 10 minutes (3 seconds pulse ON 
and 10 seconds pulse OFF). Both mammalian and bacterial lysates were then centrifuged at 
38800×g for 1 hour at 4°C, and the supernatants passed through a 0.45 µm filter (Millipore). 
The soluble fractions were loaded onto a 5 mL HisTrap™ FF Nickel Sepharose Column (GE 
Healthcare), previously equilibrated with binding buffer (50 mM Tris-HCl pH 8, 300 mM 
NaCl, 10 mM imidazole, 5% glycerol). The bound species were eluted in 1.5 mL fractions, 
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applying a 0-60% gradient in 30 column volumes (CVs) of elution buffer (50 mM Tris-HCl 
pH 8, 300 mM NaCl, 300 mM imidazole, 5 % glycerol). The fractions containing hsEH were 
pooled and dialysed at 4°C overnight, in 20 mM MOPS pH 7.4, 75 mM NaCl, 1 mM EDTA, 
2 mM DTT.  
Benzylthio-Sepharose (BTS) chromatography 
The Benzylthio-Sepharose (BTS) is an improved affinity chromatography resin for the 
purification of Epoxide Hydrolases. The resin was synthesised in-house using a protocol 
adapted from Winxtrom et al. [28]. 10 mL of CL-6B® Sepharose resin (Sigma Aldrich) were 
poured onto a 15 mL polypropylene gravity column (Pierce), and washed with 10 CVs of 
water, 10 CVs of 50% MeOH, and 10 CVs of 0.1 M NaOH. The resin was then transferred in 
a 100 mL frosted neck round-bottom flask, containing 20 mL of 0.3 M NaOH, and 2 mL of 
1,4-butanediol diglycidyl ether (activation solution), then cooled down for 30 minutes on ice 
while shaking. 60 mg of NaBH4 were added, and the epoxy-activation of the Sepharose was 
carried out at room temperature for 5 hours on an orbital shaker in a fume hood (note that the 
flask was sealed with an aerated rubber stopper, to allow the release of the H2 generated by 
the reaction). The activated resin was transferred in a sintered-glass funnel and washed with 
20 CVs of water pH 6, 20 CVs of 50% MeOH, 20 CVs of MeOH, 20 CVs of 50% MeOH, 
and 20 CVs of water pH 6. The resin was resuspended in 20 mL of activation solution, added 
with 50 mL of benzyl mercaptan, and left to swirl for 24 hours at room temperature in a fume 
hood. The derived resin was transferred on a sintered glass funnel, and washed with 40 CVs 
of 50% MeOH, 40 CVs of MeOH, 40 CVs of 50% MeOH, 40 CVs of water, 40 CVs of 0.5 
M NaCl, 40 CVs of water, 40 CVs of 0.001 M HCl to hydrolyse the unreacted epoxy-groups, 
40 CVs of water, and 40 CVs of 50% EtOH. The resin was then split in aliquots of 2.5 mL in 
gravity columns and washed with 10 CVs of EtOH. The final BTS resin was stored at 4°C in 
0.1% of butylated hydroxyanisole.  
Proteins subjected to dialysis after IMAC purification were loaded onto the BTS resin 
previously equilibrated with binding buffer (20 mM MOPS pH 7.4, 75 mM NaCl, 1 mM 
EDTA, 2 mM DTT, 5% glycerol). After washing the column with 2.5 CVs of binding buffer, 
hsEH proteins were eluted with 10 CVs of elution buffer (20 mM MOPS pH 7.4, 75 mM 
NaCl, 1 mM EDTA, 2 mM DTT, 5% glycerol, 1 mM 2-benzoyl-3-phenyloxirane). Purity and 
state of the protein were verified by SDS-PAGE, and the fractions containing protein were 
dialysed at 4°C overnight in 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 3 mM KH2PO4, 
pH 7.4, 0.2 mM EDTA, 1 mM DTT. 
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Size-exclusion chromatography (SEC) 
Protein samples were concentrated up to 5 mL, filtered with 0.2 µm filters (Millipore) and 
loaded onto a HiLoad 16/600 Superdex 75pg SEC (GE Healthcare), previously equilibrated 
with 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 3 mM KH2PO4, pH 7.4, 0.2 mM EDTA, 
1 mM DTT, 5 % glycerol. Fractions containing hsEH proteins were pooled together and 
dialysed overnight at 4°C in 50 mM TRIS-HCl pH 7.4, 300 mM NaCl, 20% glycerol. After 
dialysis, samples were concentrated to 1 mg/mL (concentration adjusted according to the 
theoretical molecular weight and extinction coefficient, obtained using the ProtPARAM 
ExPASY tool [29]), flash frozen in small aliquots using liquid nitrogen, and stored at -80°C.  
Western blots 
For immunoblotting, the samples were initially run on SDS-PAGE (using Laemmli protocol 
[30]) at 170 V for 60 minutes, to be then transferred onto a PVDF membrane (Sigma) for 1 
hour at 100 V (cooled with ice packs). The membranes were blocked with PBS and 10% 
milk, at room temperature in agitation for 1 hour. After three washes of 10 minutes with 5 
mL PBS-T (PBS, 0.1% Tween®-20), the membranes were exposed to the primary antibody in 
PBS-T added with 2% milk (mouse anti-6×His-tag 1:5000 – Stratech CSB-MA000011M0m; 
rabbit anti-hsEH 1:1000 – Stratech CSB-PA007735LA01HU), shaken for 1 hour at room 
temperature. After being washed three times for 10 minutes with 5 mL PBS-T, the 
membranes were exposed to HRP-conjugated secondary antibody in PBS-T added with 2% 
milk (goat-anti-mouse 1:5000 – Dako P0447; goat-anti-rabbit 1:2000 – Dako P0448). After 1 
hour in agitation at room temperature, the membranes were washed three times for 10 
minutes, two times with 5 mL PBS-T, and a last time with PBS. The detection was carried 
out using the Enhanced Chemiluminescent Luminol (Promega).  
Electrospray ionisation mass spectrometry (ESI-MS) 
The intact protein MS experiments were performed using a maXis (Bruker) calibrated using 
the tuning mix ES-TOF (ESI) positive (Agilent). The proteins were dialysed overnight at 4°C 
in 25 mM HEPES pH 7.4, 300 mM NaCl, 10% glycerol, 1 mM DTT, to be then concentrated 
to 5-10 mg/mL. The samples for ESI-MS were prepared diluting the proteins at a final 
concentration of 60 µg/mL in 0.1 % formic acid, to be then loaded onto a Hamilton syringe 
and directly injected into the spectrometer using a motorised pump with a flow rate of 10-50 
µL/min. The spectra were recorded for 3 minutes and a spectral rate of 1 Hz, with an end 
plate offset of -500 V, a capillary voltage of -4500 V, and a nebuliser pressure of 3.0 Bar. The 
detection of the spectra was performed setting the funnel and multipole RF at 400 Vpp, 
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tuning the ISCID energy between 80 and 110 eV to optimise the signal-to-noise ratio, and 
selecting an ion energy of 3 eV.  
Specific activity measurements 
The enzyme specific activity was evaluated using a rapid continuous spectrofluorometric 
method developed by Wolf et al. [31]. The assay utilises the synthetic substrate 3-phenyl-
cyano(6-methoxy-2-naphthalenyl) methyl ester-2-oxiraneacetic acid (PHOME – Cayman), 
which is hydrolysed by Epoxide Hydrolases, generating a detectable fluorescent end-product 
called 6-methoxy-2-naphtaldehyde (6M2N). The recombinant enzymes were thawed on ice 
and diluted with reaction buffer (25 mM TRIS-HCl pH 7.4) to 0.2, 0.4, 0.8, 1.6, 4, 8 µM 
concentrations, in previously cooled tubes. The aliquots were mixed with 10 µM TCEP for 
15 minutes on ice and diluted 1:40 v/v in reaction buffer in a 96-well polystyrene microtiter 
plate (Thermo Scientific). A fresh 0.4 mM solution of PHOME was prepared in DMSO, to be 
then diluted 1:40 v/v in the 96-well plate. The measurements of the relative fluorescence 
units (RFUs) were carried out for 20 minutes using a POLARstar Omega (BMG Labtech), 
with the following setup: excitation wavelength 330 nm, emission wavelength 460 nm, 
detection every 45 seconds, gain 750, and 30°C constant temperature. Measurements were 
performed in four replicates, and each experiment was repeated three times. For 
quantification purposes, a conversion curve was built reporting the 6M2N fluorescence as 
function of the fluorophore concentration. A series of 6M2N (Sigma) solutions with 
concentrations ranging between 0.01 and 10 mM were prepared in DMSO and diluted 1:25 
v/v into reaction buffer. These solutions were then diluted 1:4 v/v into buffer in the 96-well 
plate and an endpoint fluorescence measurement was performed (same setting as before). The 
correlation between the fluorescence detected and the nmol of 6M2N was calculated by linear 
regression, and the slope used to convert the RFUs of the specific activity measurements into 
moles of product. Upon determination of the specific activity, the Turnover Frequency (TOF) 
was calculated. The hsEH FL and CTD TOFs were compared with one-tailed homoscedastic 
t-test and reported in the plots as average ± SEM. The statistical significance was set up at 
minimum p 0.05.  
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Results and Discussion 
Cloning of hsEH FL in TOPO pcDNA™3.1 
Based on the cDNA sequence of the hsEH FL kindly provided by Dr C Morisseau and the 
instructions of the pcDNA3.1 Directional TOPO® Expression Kit, a set of primers were 
designed (Table 1) to PCR-amplify the region corresponding to the hsEH FL cDNA. The 
amplification was confirmed by electrophoresis. The TOPO cloning reaction was set up 
mixing the blunt ended PCR product obtained and the pcDNA™3.1D/V5-His TOPO® vector. 
After transformation of the One shot® TOP10 E. Coli competent cells, confirmation of 
successful cloning was attained by sequencing of cDNA extracted from one of the colonies 
obtained (Supplementary material A). 
Cloning of hsEH CTD in pET3a 
Based on the cDNA sequence of the hsEH FL, a set of “chimeric” primers were designed 
(Table 2) to PCR-amplify the region corresponding to hsEH CTD cDNA (amino acids 230-
555). The amplification of the PCR product, as well as the successful double digestion of the 
pET3a vector with BamHI/PstI were confirmed by electrophoresis. The IN-fusion reaction 
was set up and the mixture was transformed in homemade competent DH5α C2987 E. coli 
cells. The successful cloning was confirmed by sequencing of cDNA (Supplementary 
material B), extracted from one of the colonies obtained.  
Optimisation of the expression conditions of hsEH CTD in E. coli 
Nishi et al.[23] previously reported a protocol of expression of hsEH FL in E. coli 
BL21(DE3) using the auto-induction media ZYP5052, given that induction with isopropyl-β-
D-thiogalactopyranoside (IPTG) led to recombinant protein accumulation in inclusion bodies. 
We tested whether IPTG induction of Ros2TM(DE3) cultured in Luria Broth or Terrific Broth 
produced insoluble hsEH CTD: in agreement with what was observed for the full-length 
recombinant enzyme [23], the CTD was also yielded exclusively in inclusion bodies at 
different induction temperatures, IPTG concentration and induction times (data not shown). 
However, using the autoinduction ZYP5052 media, the amount of hsEH CTD present in the 
soluble fraction increased noticeably. Transformed Ros2TM(DE3) cells were cultured at 37°C, 
up to three different levels of optical density (OD600nm) (0.5, 1, and 1.5), then the temperature 
was lowered to 18°C and the cells cultured for either 16 or 24 hours. Although most of the 
protein was still found in the insoluble fractions, detectable levels of soluble protein were 
observed when the cells were cultured at 37ºC up to an OD600 of 0.5, followed by 24 hours 
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incubation at 18ºC (Figure1). These optimised expression conditions were used for large-
scale cultures. 2 L Erlenmeyer flasks were filled up with a volume of maximum 1 L of 
ZYP5052, to allow an adequate aeration of the medium during the long growth. Expression 
tests of the cultures were in agreement with the small-scale expression tests: most of the 
protein was insoluble, but detectable levels of soluble hsEH CTD were retained in solution. 
Purification of hsEH FL  
Upon transfection of HEK293-F cells and expression of recombinant hsEH FL, pellets of ~5 
g of dry cells were obtained by centrifugation and stored at -20°C. The cells were broken, and 
the lysate prepared for the purification. Taking advantage of the His-tag engineered at the C-
terminus of the protein, the first stage of the hsEH FL purification was a Nickel IMAC. 
Figure 2A shows the elution profile of the cell lysate through the HisTrap™ FF Nickel 
Sepharose Column. The SDS-PAGE analysis of the eluted fractions revealed the presence of 
hsEH FL in the peak eluted at approximately 22% of elution buffer, corresponding to about 
70 mM imidazole (Figure 2B). The fractions containing the protein of interest were dialysed 
overnight and loaded onto the BTS column, an affinity resin able to bind hsEH through the 
interaction of its CTD and the benzyl mercaptan moieties immobilised on Sepharose units 
[28]. SDS-PAGE analysis showed an improvement in the purity of hsEH FL (Figure 2C) 
following this second purification step. As a final purification step, SEC was performed with 
the aim of removing any residual contaminant and preparing the protein for biochemical 
analysis. The SEC chromatogram, shown in Figure 2D, indicated that the protein eluted in 
two peaks. The first peak showed an elution volume above the void volume of the column 
used, suggesting that part of the protein aggregated. The second peak exhibited an 
approximate elution volume of 50 mL, and the SDS PAGE analysis (Figure 2E) revealed that 
it contained the hsEH FL. The fractions corresponding to the former peak were pooled 
together, yielding around 2 mg of protein from only 250 mL of transfected HEK293-F cells.  
Purification of hsEH CTD  
After expression of hsEH CTD in Ros2TM(DE3) cells, pellets of 10-15 g/L of cells were 
harvested. As per the full-length protein, the first step of purification was a Ni2+-IMAC, 
taking advantage of the His-tag engineered at the N-terminus of the construct. The elution 
profile showed two peaks (Figure 3A), of which only the second contained hsEH CTD 
(Figure 3B). The protein was then subjected to BTS affinity chromatography, obtaining a 
significant improvement of the purity (Figure 3C). A final SEC chromatography step was 
performed revealing that hsEH CTD eluted in a single and sharp peak (Figure 3E), indicative 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
13 
 
of a monomeric and monodisperse protein. The final sample showed high purity by SDS 
PAGE analysis (Figure 3E). Approximately 20 mg of pure protein were yielded from 3 L of 
bacterial culture.  
Characterisation of hsEH CTD and FL 
Electrospray ionisation mass spectrometry (ESI-MS) and Western blotting confirmed the 
identity of the purified proteins. The ESI-MS experiments were performed spraying hsEH 
CTD and FL in positive ionisation conditions, detecting the m/z intensity of the species in 
solution. The spectra showed a Gaussian-type distribution of peaks ranging from m/z 1275.2 
to 2475.7 for the CTD, and 1196.3 to 2289.7 m/z for the FL (Figure 4A and C). Through 
maximum entropy deconvolution, the plots shown in Figure 4B and D were generated. In the 
case of hsEH CTD, the mass profile was dominated by a species with a molecular weight of 
39497.9 Da, virtually identical to the expected mass of 39498.2 Da computed in ProtParam. 
The mass profile of hsEH FL was dominated by a species with a molecular weight of 67582.1 
Da, corresponding to the expected mass of the recombinant protein upon N-terminal 
methionine excision [32] (67711.25 Da – 131.19 Da = 67580.06 Da) (Figure 4C). In addition 
to the main species, additional minor peaks at higher masses could be detected, attributed to 
counter ions bound to hsEH FL.  
Western blotting analyses were performed on purified hsEH CTD and FL, stained with two 
different primary antibodies: a mouse anti-His-tag monoclonal antibody (taking advantage of 
the His-tag engineered in the recombinant enzymes) (Figure 5A and C) and a rabbit anti-
human bifunctional Epoxide Hydrolase 2 (Figure 5B and D). With both antibodies, it was 
detected only one band at the expected molecular weight for both hsEH CTD and FL, 
confirming the nature and the high purity of the protein samples.  
Western Blot and ESI-MS experiments confirmed the identity of the recombinant hsEH CTD 
and FL expressed and purified from E. coli and HEK293-F cells respectively. 
Specific activity measurements 
The specific activity of hsEH CTD and FL was determined via a spectrofluorometric assay, 
using the synthetic substrate (PHOME) [31]. Protein solutions with increasing concentrations 
of hsEH CTD and FL were prepared and diluted in the reaction buffer in adequate 
microplates. A saturating final concentration of the substrate PHOME was then added, and 
the fluorescence signal was monitored for 20 minutes. Figure 6A reports the raw data 
obtained for hsEH CTD and FL, showing the expected fluorescence signal increase as 
function of protein concentration.  
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For accurate analysis, only the linear window of fluorescence increments between 0 and 10 
minutes of detection was considered, corresponding to substrate-saturating conditions. The 
RFUs of the linear interval were transformed in nmol of 6M2N, using the conversion 
coefficient (Supplementary material C). The initial velocities of substrate conversion were 
determined as slopes of the straight lines obtained by linear regression (R2 ≥ 0.9) (Figure 6B) 
and plotted versus the corresponding nmol of enzyme. The specific activity was determined 
by linear regression of the data points and further considered only when R2 ≥ 0.9 (Figure 6C). 
The experiments were repeated at least three times, obtaining average specific activities of 
67.64 ± 12.78 and 36.29 ± 4.63 pmol·min-1·mg-1 for hsEH CTD and FL respectively. From 
the specific activity values obtained, the average TOF was calculated, to normalise by the 
number of available active sites, and compared with a one-tailed homoscedastic t-test (Figure 
7). The hsEH CTD and FL exhibited TOF of respectively 2.67 ± 0.51 and 2.46 ± 0.31 
nmol·min-1·nmolenz-1. The t-test did not reveal any significant difference of the average TOF 
of hsEH CTD and FL, as anticipated, as that the N-terminal Domain is not expected to be 
involved in the epoxy-groups hydrolysis [9].  
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Conclusion 
hsEH is considered a key regulator of the cardiovascular homeostasis, a role exerted through 
the hydrolysis of endothelial signalling modulators termed epoxyeicosatrienoic acids (EETs) 
[8]. Accumulating evidence indicate that hsEH inhibition may be a potential strategy to 
increase the bioavailability of the EETs and enhance their beneficial cardioprotective 
activities. At the first stages of the hsEH inhibitors research, the enzyme used to be isolated 
from organs of different animal sources such as rats, mice, monkeys, and humans, through 
tissue homogenisation, ultracentrifugation, and enzymatic characterisation [33]. Such method 
was of inestimable help to understand localisation [34], function [35], and substrate 
specificity [36] of the mammalian sEH enzymes. Nonetheless, yields and purity were not 
sufficient to carry out structural or accurate biophysical investigations. It is only with the 
advent of sEH recombinant expression in S. frugiperda [37] that the first structure of murine 
sEH became available [1]. Since then, almost 100 structures have been deposited in the 
RCSB PDB, of both murine and human recombinant sEH, purified from insect cells. These 
structures showed many diverse compounds interacting with the enzyme, providing a 
precious tool for the characterisation and discovery of hsEH inhibitors. However, baculovirus 
protein expression is time-consuming and sometime technically challenging, welcoming the 
development of simpler and more efficient protocols of recombinant expression of the 
enzyme. Nishi et al [23] reported a protocol of expression and purification of the full length 
hsEH from E. coli BL21(DE3) cells, obtaining around 2 mg/L of pure and active protein: 
nonetheless, in our hands, this method yielded even lower amounts of pure hsEH. We have 
therefore developed alternative expression and purification methods of both full-length 
protein and its functional C-terminal domain, which is necessary and sufficient for the EETs 
epoxy-hydrolytic activity of the enzyme. hsEH FL was obtained from mammalian HEK293-F 
cells, obtaining around 2 mg of protein from only 250 mL of culture. The optimised 
expression and purification of hsEH CTD using bacterial expression, the fastest and cheapest 
method of protein production available, yielded approximately 6 mg of pure protein per L of 
culture. Moreover, we herein demonstrated that the FL and CTD exhibited virtually identical 
turnover frequencies, suggesting that the CTD in isolation can be utilised in future studies of 
hsEH epoxy hydrolytic enzymatic activity and inhibition.  
In conclusion, we have provided new tools to prepare active hsEH full-length or CTD, which 
will assist future drug discovery studies and investigations of its biological function and 
mechanisms.   
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
16 
 
Acknowledgements 
The authors thank the British Heart Foundation for financial support (grant PG/15/26/31373). 
GA was supported by a BHF interdisciplinary PhD studentship from BHF Centre of 
Excellence award, King’s College London. We thank Paul Brown (Protein Production 
Facility, King’s College London) for assistance in the cloning stage. GA and MRC thank the 
Centre for Biomolecular Spectroscopy funded by a capital award by the Wellcome Trust.   
Author’s contribution 
All the authors contributed to the planning of the study. GA performed cloning and 
optimisation of bacterial expression of hsEH CTD, development and optimisation of 
purification of hsEH FL and CTD, characterisation of hsEH FL and CTD, and their specific 
activity measurements. RLC carried out cloning and optimisation of mammalian expression 
of the hsEH FL. GA, RLC, and MRC contributed to the writing of the manuscript. All the 
authors contributed to the results discussion. MRC and PE obtained funding for this work. 
Declaration of interest 
Conflicts of interest: none.  
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
17 
 
Bibliography 
[1] M. a Argiriadi, C. Morisseau, B.D. Hammock, D.W. Christianson, Detoxification of 
environmental mutagens and carcinogens: structure, mechanism, and evolution of liver 
epoxide hydrolase., Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 10637–10642. 
doi:10.1073/pnas.96.19.10637. 
[2] M.A. Argiriadi, C. Morisseau, M.H. Goodrow, D.L. Dowdy, B.D. Hammock, D.W. 
Christianson, Binding of alkylurea inhibitors to epoxide hydrolase implicates active 
site tyrosines in substrate activation, J. Biol. Chem. 275 (2000) 15265–15270. 
doi:10.1074/jbc.M000278200. 
[3] G.A. Gomez, C. Morisseau, B.D. Hammock, D.W. Christianson, Structure of human 
Epoxide Hydrolase reveals mechanistic inferences on bifunctional catalysis in epoxide 
and phosphate ester hydrolysis, 43 (2004) 4716–4723. doi:10.1021/bi036189j. 
[4] C. Morisseau, N.H. Schebb, H. Dong, A. Ulu, P.A. Aronov, B.D. Hammock, Role of 
soluble epoxide hydrolase phosphatase activity in the metabolism of lysophosphatidic 
acids, Biochem Biophys Res Commun. 419 (2012) 796–800. 
doi:10.1016/j.bbrc.2012.02.108. 
[5] B. Borhan, D.A. Jones, F. Pinot, D.F. Grant, M.J. Kurth, B.D. Hammock, Mechanism 
of Soluble Epoxide Hydrolase, J. Biol. Chem. 270 (1995) 26923–26930. 
[6] K.H. Hopmann, F. Himo, Theoretical study of the full reaction mechanism of human 
soluble epoxide hydrolase, Chem. - A Eur. J. 12 (2006) 6898–6909. 
doi:10.1002/chem.200501519. 
[7] C. Morisseau, B.D. Hammock, Epoxide Hydrolases: mechanisms, inhibitor designs, 
and biological roles, Annu. Rev. Pharmacol. Toxicol. 45 (2005) 311–333. 
doi:10.1146/annurev.pharmtox.45.120403.095920. 
[8] J. Imig, B. Hammock, Soluble epoxide hydrolase as a therapeutic target for 
cardiovascular diseases, Nat. Rev. Drug Discov. 8 (2009) 794–805. 
doi:10.1038/nrd2875.Soluble. 
[9] T.R. Harris, B.D. Hammock, Soluble epoxide hydrolase: gene structure, expression 
and deletion, Gene. 526 (2013) 61–74. doi:10.1016/j.gene.2013.05.008. 
[10] J.D. Imig, Epoxides and soluble Epoxide Hydrolase in cardiovascular physiology, 
Physiol. Rev. 92 (2012) 101–30. doi:10.1152/physrev.00021.2011. 
[11] H. Qiu, N. Li, J.-Y. Liu, T.R. Harris, B.D. Hammock, N. Chiamvimonvat, Soluble 
Epoxide Hydrolase inhibitors and heart failure, Cardiovasc. Ther. 29 (2011) 99–111. 
doi:10.1111/j.1755-5922.2010.00150.x. 
[12] H.C. Shen, B.D. Hammock, Discovery of inhibitors of soluble Epoxide Hydrolase: A 
target with multiple potential therapeutic indications, J. Med. Chem. 55 (2012) 1789–
1808. doi:10.1021/jm201468j. 
[13] D. Chen, R. Whitcomb, E. MacIntyre, V. Tran, Z.N. Do, J. Sabry, D. V. Patel, S.K. 
Anandan, R. Gless, H.K. Webb, Pharmacokinetics and Pharmacodynamics of AR9281, 
an Inhibitor of Soluble Epoxide Hydrolase, in Single- and Multiple-Dose Studies in 
Healthy Human Subjects, J. Clin. Pharmacol. 52 (2012) 319–328. 
doi:10.1177/0091270010397049. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
18 
 
[14] I. Kim, C. Morisseau, T. Watanabe, B.D. Hammock, Design, synthesis, and biological 
activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase 
of increased water solubility Solubility, J. Med. Chem. 47 (2004) 2110–2122. 
[15] ClinicalTrials.gov Identifier: NCT00847899 - Evaluation of Soluble Epoxide 
Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and 
Impaired Glucose Tolerance, (2009). https://clinicaltrials.gov/ct2/show/NCT00847899. 
[16] L. Tran, A.R. Kompa, B.H. Wang, H. Krum, Evaluation of the Effects of Urotensin II 
and Soluble Epoxide Hydrolase Inhibitor on Skin Microvessel Tone in Healthy 
Controls and Heart Failure Patients, 30 (2012) 295–300. doi:10.1111/j.1755-
5922.2011.00282.x. 
[17] L. a Morgan, A.R. Olzinski, J.J. Upson, S. Zhao, T. Wang, S.H. Eisennagel, B. Hoang, 
J.R. Tunstead, J.P. Marino, R.N. Willette, B.M. Jucker, D.J. Behm, Soluble epoxide 
hydrolase inhibition does not prevent cardiac remodeling and dysfunction after aortic 
constriction in rats and mice, J. Cardiovasc. Pharmacol. 61 (2013) 291–301. 
doi:10.1097/FJC.0b013e31827fe59c. 
[18] ClinicalTrials.gov Identifier: NCT01762774 - A Study to Assess the Safety, 
Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of 
GSK2256294 in Healthy Volunteers, and Single and Repeat Doses of GSK2256294 in 
Adult Male Moderately Obese Sm, (2017).  
https://clinicaltrials.gov/ct2/show/NCT01762774?term=soluble+epoxide+hydrolase&r
ank=5. 
[19] ClinicalTrials.gov Identifier: NCT02006537 - A Study to Investigate the Safety and 
Pharmacokinetics of a Single Dose of GSK2256294 in Healthy Young Males and 
Elderly Subjects, (2017). 
https://clinicaltrials.gov/ct2/show/NCT02006537?term=soluble+epoxide+hydrolase&r
ank=6. 
[20] C. Morisseau, M.H. Goodrow, D. Dowdy, J. Zheng, J.F. Greene, J.R. Sanborn, B.D. 
Hammock, Potent urea and carbamate inhibitors of soluble epoxide hydrolases, Agric. 
Sci. 96 (1999) 8849–8854. doi:10.1073/pnas.96.16.8849. 
[21] I.H. Kim, F.R. Heirtzler, C. Morisseau, K. Nishi, H.J. Tsai, B.D. Hammock, 
Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved 
water solubility, J. Med. Chem. 48 (2005) 3621–3629. doi:10.1021/jm0500929. 
[22] L. Öster, S. Tapani, Y. Xue, H. Käck, Successful generation of structural information 
for fragment-based drug discovery, Drug Discov. Today. 20 (2015) 1104–1111. 
doi:10.1016/j.drudis.2015.04.005. 
[23] K. Nishi, I.H. Kim, S.J. Ma, Expression of the human soluble epoxide hydrolase in 
Escherichia coli by auto-induction for the study of high-throughput inhibition assays, 
Protein Expr. Purif. 69 (2010) 34–38. doi:10.1016/j.pep.2009.09.013. 
[24] A.C. Dalton, W.A. Barton, Over-expression of secreted proteins from mammalian cell 
lines, Protein Sci. 23 (2014) 517–525. doi:10.1002/pro.2439. 
[25] D. Tanaka, Y. Tsuda, T. Shiyama, T. Nishimura, N. Chiyo, Y. Tominaga, N. Sawada, 
T. Mimoto, N. Kusunose, A practical use of ligand efficiency indices out of the 
fragment-based approach: ligand efficiency-guided lead identification of soluble 
epoxide hydrolase inhibitors, J. Med. Chem. 54 (2011) 851–857. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
19 
 
doi:10.1021/jm101273e. 
[26] A.L. Throop, J. Labaer, Recombinational cloning using Gateway and In-Fusion 
cloning schemes, in: F.M. Ausubel (Ed.), Curr. Protoc. Mol. Biol., 2015: p. 
110:3.20.1-3.20.23. doi:10.1002/0471142727.mb0320s110.Recombinational. 
[27] F.W. Studier, Protein production by auto-induction in high-density shaking cultures, 
Protein Expr. Purif. 41 (2005) 207–234. doi:10.1016/j.pep.2005.01.016. 
[28] R.N. Wixtrom, M.H. Silva, B.D. Hammock, Affinity purification of cytosolic Epoxide 
Hydrolase using derivatized epoxy-activated Sepharose gels, Anal. Biochem. 169 
(1988) 71–80. doi:10.1016/0003-2697(88)90256-4. 
[29] E. Gasteiger, C. Hoogland, A. Gattiker, S. Duvaud, M.R. Wilkins, R.D. Appel, A. 
Bairoch, Protein Identification and Analysis Tools on the ExPASy Server, Proteomics 
Protoc. Handb. (2005) 571–607. doi:10.1385/1592598900. 
[30] U.K. Laemmli, Cleavage of structural proteins during assembly of head of 
bacteriophage‐T4, Nature. 227 (1970) 680–685. doi:10.1038/227680a0. 
[31] N.M. Wolf, C. Morisseau, P.D. Jones, B. Hock, B.D. Hammock, Development of a 
high-throughput screen for soluble epoxide hydrolase inhibition, Anal. Biochem. 355 
(2006) 71–80. doi:10.1016/j.ab.2006.04.045. 
[32] C. Giglione, A. Boularot, T. Meinnel, Protein N-terminal methionine excision, Cell. 
Mol. Life Sci. 61 (2004) 1455–1474. doi:10.1007/s00018-004-3466-8. 
[33] S.S. Gill, K. Ota, B. Ruebner, B.D. Hammock, Microsomal and cytosolic Epoxide 
Hydrolase in Rhesus monkey liver, and in normal and neoplastic human liver, Life Sci. 
32 (1983) 2693–2700. 
[34] S.S. Gill, B.D. Hammock, Distribution and properties of a mammalian soluble epoxide 
hydrase, Biochem. Pharmacol. 29 (1980) 389–395. doi:10.1016/0006-2952(80)90518-
3. 
[35] J. Magdalou, B.D. Hammock, 1,2-Epoxycycloalkanes: substrates and inhibitors of 
microsomal and cytosolic epoxide hydrolases in mouse liver, Biochem. Pharmacol. 37 
(1988) 2717–2722. doi:10.1016/0006-2952(88)90033-0. 
[36] D.C. Zeldin, J. Kobayashi, J.R. Falck, B.S. Winder, B.D. Hammock, J.R. Snapper, J.H. 
Capdevila, Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration 
by cytosolic epoxide hydrolase, J. Biol. Chem. 268 (1993) 6402–6407. 
[37] F. Pinot, D.F. Grant, J.K. Beetham, A.G. Parker, B. Borhan, S. Landt, A.D. Jones, 
B.D. Hammock, Molecular and biochemical evidence for the involvement of the Asp-
333-His-523 Pair in the Catalytic Mechanism of soluble Epoxide Hydrolase, J. Biol. 
Chem. 270 (1995) 7968–7974. doi:10.1074/jbc.270.14.7968. 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
20 
 
Figure captions 
Figure 1. hsEH CTD expression tests in Ros2(DE3) E. coli cultured in ZYP5052 auto-
induction media. hsEH CTD expressed well, with most of the protein being retained in the 
insoluble fractions. The best conditions for soluble proteins consisted in growing the cells at 
37°C up to an OD600nm of 0.5, followed by 24 hours at 18°C (eighth lane from left). MWM: 
molecular weight marker; B.S.: before temperature switch; T.C.: total cells; I.F.: insoluble 
fraction; S.F.: soluble fraction; OD600nm: optical density at 600 nm. 
Figure 2. Purification of hsEH FL. A. IMAC elution profile. The elution produced two 
peaks, distinguishable between fractions 5 and 42. B. SDS-PAGE analysis of IMAC. The 
second elution peak contained hsEH FL. C. SDS-PAGE analysis following BTS purification. 
Following IMAC, the sample resulted almost pure (as shown in the “Before BTS” lane). The 
BTS affinity purification removed the minor residual contaminants. D. SEC elution profile. 
The elution produced two peaks, between fractions 12 and 45. E. SDS-PAGE analysis of 
SEC fractions. The hsEH FL was eluted in the second SEC peak. MWM: molecular weight 
marker; FT: flow-through; Wash A: wash with binding buffer; Wash B: wash with elution 
buffer.  
Figure 3. Purification of hsEH CTD. A. IMAC elution profile. The elution produced two 
peaks, distinguishable between fractions 5 and 75. B. SDS-PAGE analysis of IMAC 
fractions. The second elution peak contained hsEH CTD. C. SDS-PAGE analysis following 
BTS purification. The high affinity and specificity of BTS increased significantly the purity 
of the hsEH CTD sample. D. SEC elution profile. The hsEH CTD was eluted in a single peak 
between fractions 26 and 45. E. SDS-PAGE analysis of SEC fractions. The elution peak 
showed high purity levels and no signs of degradation.  
Figure 4. ESI-MS analyses of intact hsEH CTD and FL. A. m/z detection of intact hsEH 
CTD. The m/z spectrum showed a Gaussian-type distribution of multiply charged ions 
ranging from m/z 1275.2 to 2475.7. B. Deconvolution of intact hsEH CTD m/z spectrum. 
The mass of the recombinant hsEH CTD was 39497.9 Da, virtually identical to the one 
computed with ProtParam. C. m/z detection of intact hsEH FL. The m/z spectrum showed a 
Gaussian-type distribution of multiply charged ions ranging from m/z 1196.3 to 2289.7. D. 
Deconvolution of intact hsEH FL m/z spectrum. The deconvoluted mass of the recombinant 
hsEH FL was 67582.1 Da, corresponding to the molecular weight of the protein upon N-
terminal methionine excision.  
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Figure 5. Western blotting analysis of hsEH CTD and FL. A. and C. Detection with anti-His-
tag antibody for CTD and FL respectively. B. and D. Detection with anti-hsEH antibody for 
CTD and FL respectively. Signal detection of hsEH CTD and FL revealed only one band 
with both the antibodies employed. 
Figure 6. Enzymatic specific activity measurements of hsEH CTD and FL. A. Raw RFUs 
measurements. Increasing enzyme concentrations corresponded to growing fluorescence 
signal detection. B. Conversion to nmol of product vs. time of the RFUs linear region. The 
conversion was carried out using the slope of the conversion curve reported in Supplementary 
Material C. C. Specific activity determination. The parameter was calculated as the slope of 
the curve interpolated by the data points reported.  
Figure 7. TOF comparison of hsEH CTD and FL obtained from the enzymatic specific 
activity. No significant difference of TOFs could be detected between the full-length enzyme 
and the CTD in isolation. 
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Tables 
Table 1. Primers used in the cloning of the hsEH FL into pcDNA™3.1D/V5-His-TOPO® 
vector. The primers were synthesised by Sigma.    
Table 2. Primers used in the IN-Fusion cloning of the hsEH CTD. The primers were 
synthesised by Sigma.    
 
 
 
  
Primer Sequence 
Forward 
 
5’  CACCATGACGCTGCGCGCGGCC  3’ 
 
Bold: pcDNA™3.1D/V5-His TOPO® annealing sequence to enable directional cloning 
Underlined: ATG initiation codon 
Normal:  hsEH FL cDNA annealing sequence 
Reverse 5’  CATCTTTGAGACCACCGGTGG  3’ 
Primer Sequence 
Forward 
 
5’ ACCACAGCCAGGATCCAACCTCTTGCAATCCAAGTGA 3’ 
 
Bold: pET3a annealing sequence 
Italic: BamHI restriction enzyme 
Normal: hsEH CTD cDNA annealing sequence 
Reverse 5’ GCAAGCTTGTCGACCTGCAGTCATTACATCTTTGAGACCACCGGTG 3’ 
 
Bold: pET3a annealing sequence 
Italic: PstI restriction enzyme 
Underlined: Stop Codons 
Normal: hsEH CTD cDNA annealing sequence 
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Supplementary material A 
Sequencing results of hsEH FL in TOPO pcDNA™3.1 
1    atg acg ctg cgc gcg gcc gtc ttc gac ctt gac ggg gtg ctg gcg  
 M   T   L   R   A   A   V   F   D   L   D   G   V   L   A    
46   ctg cca gcg gtg ttc ggc gtc ctc ggc cgc acg gag gag gcc ctg  
 L   P   A   V   F   G   V   L   G   R   T   E   E   A   L    
91   gcg ctg ccc aga gga ctt ctg aat gat gct ttc cag aaa ggg gga  
 A   L   P   R   G   L   L   N   D   A   F   Q   K   G   G  
136  cca gag ggt gcc act acc cgg ctt atg aaa gga gag atc aca ctt  
 P   E   G   A   T   T   R   L   M   K   G   E   I   T   L    
181  tcc cag tgg ata cca ctc atg gaa gaa aac tgc agg aag tgc tcc  
 S   Q   W   I   P   L   M   E   E   N   C   R   K   C   S  
226  gag acc gct aaa gtc tgc ctc ccc aag aat ttc tcc ata aaa gaa  
 E   T   A   K   V   C   L   P   K   N   F   S   I   K   E  
271  atc ttt gac aag gcg att tca gcc aga aag atc aac cgc ccc atg  
 I   F   D   K   A   I   S   A   R   K   I   N   R   P   M    
316  ctc cag gca gct ctc atg ctc agg aag aaa gga ttc act act gcc  
 L   Q   A   A   L   M   L   R   K   K   G   F   T   T   A  
361  atc ctc acc aac acc tgg ctg gac gac cgt gct gag aga gat ggc  
 I   L   T   N   T   W   L   D   D   R   A   E   R   D   G  
406  ctg gcc cag ctg atg tgt gag ctg aag atg cac ttt gac ttc ctg  
 L   A   Q   L   M   C   E   L   K   M   H   F   D   F   L    
451  ata gag tcg tgt cag gtg gga atg gtc aaa cct gaa cct cag atc  
 I   E   S   C   Q   V   G   M   V   K   P   E   P   Q   I  
496  tac aag ttt ctg ctg gac acc ctg aag gcc agc ccc agt gag gtc  
 Y   K   F   L   L   D   T   L   K   A   S   P   S   E   V  
541  gtt ttt ttg gat gac atc ggg gct aat ctg aag cca gcc cgt gac  
 V   F   L   D   D   I   G   A   N   L   K   P   A   R   D  
586  ttg gga atg gtc acc atc ctg gtc cag gac act gac acg gcc ctg  
 L   G   M   V   T   I   L   V   Q   D   T   D   T   A   L  
631  aaa gaa ctg gag aaa gtg acc gga atc cag ctt ctc aat acc ccg  
 K   E   L   E   K   V   T   G   I   Q   L   L   N   T   P    
676  gcc cct ctg ccg acc tct tgc aat cca agt gac atg agc cat ggg  
 A   P   L   P   T   S   C   N   P   S   D   M   S   H   G    
721  tac gtg aca gta aag ccc agg gtc cgt ctg cat ttt gtg gag ctg  
 Y   V   T   V   K   P   R   V   R   L   H   F   V   E   L  
766  ggc tcc ggc cct gct gtg tgc ctc tgc cat gga ttt ccc gag agt  
 G   S   G   P   A   V   C   L   C   H   G   F   P   E   S    
811  tgg tat tct tgg agg tac cag atc cct gct ctg gcc cag gca ggt  
 W   Y   S   W   R   Y   Q   I   P   A   L   A   Q   A   G  
856  tac cgg gtc cta gct atg gac atg aaa ggc tat gga gag tca tct  
 Y   R   V   L   A   M   D   M   K   G   Y   G   E   S   S  
901  gct cct ccc gaa ata gaa gaa tat tgc atg gaa gtg tta tgt aag  
 A   P   P   E   I   E   E   Y   C   M   E   V   L   C   K    
946  gag atg gta acc ttc ctg gat aaa ctg ggc ctc tct caa gca gtg  
 E   M   V   T   F   L   D   K   L   G   L   S   Q   A   V  
991  ttc att ggc cat gac tgg ggt ggc atg ctg gtg tgg tac atg gct  
 F   I   G   H   D   W   G   G   M   L   V   W   Y   M   A  
1036 ctc ttc tac ccc gag aga gtg agg gcg gtg gcc agt ttg aat act  
 L   F   Y   P   E   R   V   R   A   V   A   S   L   N   T     
1081 ccc ttc ata cca gca aat ccc aac atg tcc cct ttg gag agt atc  
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 P   F   I   P   A   N   P   N   M   S   P   L   E   S   I  
1126 aaa gcc aac cca gta ttt gat tac cag ctc tac ttc caa gaa cca  
 K   A   N   P   V   F   D   Y   Q   L   Y   F   Q   E   P  
1171 gga gtg gct gag gct gaa ctg gaa cag aac ctg agt cgg act ttc  
 G   V   A   E   A   E   L   E   Q   N   L   S   R   T   F  
1216 aaa agc ctc ttc aga gca agc gat gag agt gtt tta tcc atg cat  
 K   S   L   F   R   A   S   D   E   S   V   L   S   M   H    
1261 aaa gtc tgt gaa gcg gga gga ctt ttt gta aat agc cca gaa gag  
 K   V   C   E   A   G   G   L   F   V   N   S   P   E   E   
1306 ccc agc ctc agc agg atg gtc act gag gag gaa atc cag ttc tat  
 P   S   L   S   R   M   V   T   E   E   E   I   Q   F   Y  
1351 gtg cag cag ttc aag aag tct ggt ttc aga ggt cct cta aac tgg  
 V   Q   Q   F   K   K   S   G   F   R   G   P   L   N   W   
1396 tac cga aac atg gaa agg aac tgg aag tgg gct tgc aaa agc ttg  
 Y   R   N   M   E   R   N   W   K   W   A   C   K   S   L  
1441 gga cgg aag atc ctg att ccg gcc ctg atg gtc acg gcg gag aag 
 G   R   K   I   L   I   P   A   L   M   V   T   A   E   K  
1496 gac ttc gtg ctc gtt cct cag atg tcc cag cac atg gag gac tgg  
 D   F   V   L   V   P   Q   M   S   Q   H   M   E   D   W   
1541 att ccc cac ctg aaa agg gga cac att gag gac tgt ggg cac tgg  
 I   P   H   L   K   R   G   H   I   E   D   C   G   H   W  
1586 aca cag atg gac aag cca acc gag gtg aat cag atc ctc att aag  
 T   Q   M   D   K   P   T   E   V   N   Q   I   L   I   K  
1631 tgg ctg gat tct gat gcc cgg aac cca ccg gtg gtc tca aag atg 
 W   L   D   S   D   A   R   N   P   P   V   V   S   K   M   
1676 aag ggt caa gac aat tct gca gat atc cag cac agt ggc ggc cgc  
 K   G   Q   D   N   S   A   D   I   Q   H   S   G   G   R  
1721 tcg agt cta gag ggc ccg cgg ttc gaa ggt aag cct atc cct aac  
 S   S   L   E   G   P   R  F   E   G   K   P   I   P   N    
1766 cct ctc ctc ggt ctc gat tct acg cgt acc ggt cat cat cac cat  
 P   L   L   G   L   D   S   T   R   T   G   H   H   H   H 
1811 cat cat tga 
 H   H  STOP 
Bold: protein sequence 
Grey: His-tag 
Underlined: V5-epitope 
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Supplementary material B 
Sequencing results of hsEH CTD in pET3a 
1   atg cat cac cat cac cat cac tcg acc gaa aac ctg tat ttt cag  
 M   H   H   H   H   H   H   S   T   E   N   L   Y   F   Q    
46  ggc tcg agc acc tct tgc aat cca agt gac atg agc cat ggg tac 
     G   S   S   T   S   C   N   P   S   D   M   S   H   G   Y  
91  gtg aca gta aag ccc agg gtc cgt ctg cat ttt gtg gag ctg ggc  
V   T   V   K   P   R   V   R   L   H   F   V   E   L   G   
136 tcc ggc cct gct gtg tgc ctc tgc cat gga ttt ccc gag agt tgg  
S   G   P   A   V   C   L   C   H   G   F   P   E   S   W 
181 tat tct tgg agg tac cag atc cct gct ctg gcc cag gca ggt tac  
Y   S   W   R   Y   Q   I   P   A   L   A   Q   A   G   Y   
226 cgg gtc cta gct atg gac atg aaa ggc tat gga gag tca tct gct  
R   V   L   A   M   D   M   K   G   Y   G   E   S   S   A  
271 cct ccc gaa ata gaa gaa tat tgc atg gaa gtg tta tgt aag gag  
P   P   E   I   E   E   Y   C   M   E   V   L   C   K   E  
316 atg gta acc ttc ctg gat aaa ctg ggc ctc tct caa gca gtg ttc  
M   V   T   F   L   D   K   L   G   L   S   Q   A   V   F  
361 att ggc cat gac tgg ggt ggc atg ctg gtg tgg tac atg gct ctc  
I   G   H   D   W   G   G   M   L   V   W   Y   M   A   L    
406 ttc tac ccc gag aga gtg agg gcg gtg gcc agt ttg aat act ccc  
F   Y   P   E   R   V   R   A   V   A   S   L   N   T   P  
451 ttc ata cca gca aat ccc aac atg tcc cct ttg gag agt atc aaa  
F   I   P   A   N   P   N   M   S   P   L   E   S   I   K  
496 gcc aac cca gta ttt gat tac cag ctc tac ttc caa gaa cca gga  
A   N   P   V   F   D   Y   Q   L   Y   F   Q   E   P   G  
541 gtg gct gag gct gaa ctg gaa cag aac ctg agt cgg act ttc aaa  
V   A   E   A   E   L   E   Q   N   L   S   R   T   F   K  
586 agc ctc ttc aga gca agc gat gag agt gtt tta tcc atg cat aaa  
S   L   F   R   A   S   D   E   S   V   L   S   M   H   K  
631 gtc tgt gaa gcg gga gga ctt ttt gta aat agc cca gaa gag ccc  
V   C   E   A   G   G   L   F   V   N   S   P   E   E   P  
676 agc ctc agc agg atg gtc act gag gag gaa atc cag ttc tat gtg  
S   L   S   R   M   V   T   E   E   E   I   Q   F   Y   V  
721 cag cag ttc aag aag tct ggt ttc aga ggt cct cta aac tgg tac  
Q   Q   F   K   K   S   G   F   R   G   P   L   N   W   Y  
766 cga aac atg gaa agg aac tgg aag tgg gct tgc aaa agc ttg gga  
R   N   M   E   R   N   W   K   W   A   C   K   S   L   G    
811 cgg aag atc ctg att ccg gcc ctg atg gtc acg gcg gag aag gac  
R   K   I   L   I   P   A   L   M   V   T   A   E   K   D    
856 ttc gtg ctc gtt cct cag atg tcc cag cac atg gag gac tgg att  
F   V   L   V   P   Q   M   S   Q   H   M   E   D   W   I    
901 ccc cac ctg aaa agg gga cac att gag gac tgt ggg cac tgg aca  
P   H   L   K   R   G   H   I   E   D   C   G   H   W   T  
946 cag atg gac aag cca acc gag gtg aat cag atc ctc att aag tgg  
Q   M   D   K   P   T   E   V   N   Q   I   L   I   K   W   
991 ctg gat tct gat gcc cgg aac cca ccg gtg gtc tca aag atg tga 
L   D   S   D   A   R   N   P   P   V   V   S   K   M  STOP 
Grey: His-tag 
Bold underlined: TEV-cleavage site 
Bold: protein sequence 
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Supplementary material C 
Conversion curve 
The fluorescence detected by the spectrofluorometer in the specific activity measurements is 
determined in relative fluorescence units (RFUs). However, for quantification purposes the 
RFUs must be converted into moles of the fluorescent end-product of the reaction, namely 6-
methoxy-2-naphthaldehyde (6M2N). For this purpose, solutions of the fluorescent product 
were prepared in DMSO at known concentrations and diluted with the reaction buffer in the 
microplates, to then detect their fluorescence at 460 nm. The correlation between the 
fluorescence detected and the nmol of fluorophore was calculated by linear regression 
(Figure S1). The slope of the curve represented the so-called conversion coefficient, used to 
transform the fluorescence units in nmol of 6M2N.  
 
 
 
Figure S1. RFUs conversion curve.  
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Highlights  
• hsEH is a key regulator of cardiovascular homeostasis  
• A HEK293-F mammalian expression system for hsEH full-length (FL) was developed  
• An E. coli expression system for the hsEH C-terminal Domain (CTD) was established  
• Both proteins exhibited the same enzymatic specific activity in vitro  
• The CTD preparation provides benefits of easy operation, and high yield and purity  
 
